Cetrorelix in Reproductive Medicine

Overview

Journal F S Rep

Specialty Reproductive Medicine

Date 2023 May 24

PMID 37223762

Authors

Sebastian Findeklee

Prof Klaus Diedrich

Affiliations

Soon will be listed here.

Abstract

This book chapter presents the most important clinical aspects concerning the gonadotropin-releasing hormone antagonist cetrorelix and its importance in reproductive medicine. After an overview of the historical milestones in the development and establishment of cetrorelix in the context of ovarian stimulation treatment, its dosage, effects, and side effects are evaluated. The chapter terminates with a conclusion emphasizing the ease of use and the increase in patient safety because of a significantly reduced risk of ovarian hyperstimulation syndrome with cetrorelix compared with the agonist protocol.

Citing Articles

GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy.

Patel S, Saxena B, Mehta P, Niazi S Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861098 PMC: 11768417. DOI: 10.3390/ph18010036.

Smooth muscle electromyography for detecting major alterations in the estrus cycle in rats.

Szucs K, Vigh D, Mirdamadi M, Samavati R, Barna T, Schaffer A PLoS One. 2024; 19(8):e0307932.

PMID: 39116057 PMC: 11309437. DOI: 10.1371/journal.pone.0307932.

Effectiveness and safety of GnRH antagonist originator and generic in real-world clinical practice: a retrospective cohort study.

Cao M, Hu Y, Xiao J, Li S, Lin Y, Liu J Front Endocrinol (Lausanne). 2024; 15:1358278.

PMID: 38948522 PMC: 11211621. DOI: 10.3389/fendo.2024.1358278.

Peptide Therapeutics: Unveiling the Potential against Cancer-A Journey through 1989.

Al Musaimi O Cancers (Basel). 2024; 16(5).

PMID: 38473389 PMC: 11326481. DOI: 10.3390/cancers16051032.

References

Diedrich K, Diedrich C, Santos E, Zoll C, Al-Hasani S, Reissmann T . Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod. 1994; 9(5):788-91. DOI: 10.1093/oxfordjournals.humrep.a138597. View

Al-Inany H, Abou-Setta A, Aboulghar M . Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev. 2006; (3):CD001750. DOI: 10.1002/14651858.CD001750.pub2. View

Devroey P, Adriaensen P . OHSS Free Clinic. Facts Views Vis Obgyn. 2014; 3(1):43-5. PMC: 3991410. View

Schally A . New approaches to the therapy of various tumors based on peptide analogues. Horm Metab Res. 2008; 40(5):315-22. DOI: 10.1055/s-2008-1073142. View

Engel J, Schultze-Mosgau A, Diedrich K . Five years' clinical use of GnRH antagonists: evaluation of safety and allergic potential. Reprod Biomed Online. 2013; 10 Suppl 3:61-5. DOI: 10.1016/s1472-6483(11)60392-1. View

Ovarian Stimulation T, Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P . ESHRE guideline: ovarian stimulation for IVF/ICSI. Hum Reprod Open. 2020; 2020(2):hoaa009. PMC: 7203749. DOI: 10.1093/hropen/hoaa009. View

Leroy I, dAcremont M, Brailly-Tabard S, Frydman R, de Mouzon J, Bouchard P . A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge. Fertil Steril. 1994; 62(3):461-7. DOI: 10.1016/s0015-0282(16)56932-5. View

Albano C, Felberbaum R, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K . Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod. 2000; 15(3):526-31. DOI: 10.1093/humrep/15.3.526. View

Reissmann T, Schally A, Bouchard P, Riethmiiller H, Engel J . The LHRH antagonist cetrorelix: a review. Hum Reprod Update. 2000; 6(4):322-31. DOI: 10.1093/humupd/6.4.322. View

10.

Griesinger G, Diedrich K, Devroey P, Kolibianakis E . GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2005; 12(2):159-68. DOI: 10.1093/humupd/dmi045. View

11.

Ludwig M, Albano C, Olivennes F, Felberbaum R, Smitz J, Ortmann O . Plasma and follicular fluid concentrations of LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for IVF. Arch Gynecol Obstet. 2002; 266(1):12-7. DOI: 10.1007/pl00007490. View

12.

Howles C . The place of gonadotrophin-releasing hormone antagonists in reproductive medicine. Reprod Biomed Online. 2002; 4 Suppl 3:64-71. DOI: 10.1016/s1472-6483(12)60120-5. View

13.

Reissmann T, Felberbaum R, Diedrich K, Engel J, Comaru-Schally A, Schally A . Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod. 1995; 10(8):1974-81. DOI: 10.1093/oxfordjournals.humrep.a136219. View

14.

Devroey P, Polyzos N, Blockeel C . An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod. 2011; 26(10):2593-7. DOI: 10.1093/humrep/der251. View

15.

Guillemin R . Purification, isolation, and primary structure of the hypothalamic luteinizing hormone-releasing factor of ovine origin. A historical account. Am J Obstet Gynecol. 1977; 129(2):214-8. DOI: 10.1016/0002-9378(77)90749-9. View